

Gibson Dunn Advises Fairmount Funds on \$110 Million PIPE Transaction for Inhibikase Therapeutics

Firm News | October 9, 2024

Gibson, Dunn & Crutcher LLP advised Fairmount Funds on its participation in the \$110 million PIPE transaction for Inhibikase Therapeutics. The Gibson Dunn corporate team was led by partners Branden Berns and Ryan Murr.

Related People

[Branden C. Berns](#)

[Ryan A. Murr](#)

Related Capabilities

[Capital Markets](#)

[Emerging Companies / Venture Capital](#)

[Finance](#)

[Life Sciences](#)

[Mergers and Acquisitions](#)

[Private Equity](#)